ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: While House Floats Healy’s Name For NIH Post; USC To Enhance Norris Center With NCI Grants

September 14, 1990

Excerpts From Potti’s Application to Practice Medicine In South Carolina

December 9, 2011

NCI Programs: NCI Drug Screening To Take More Targeted Approach; BSA Okays Plan To Support New MA Contracts

April 3, 1998

Four More COP Awards Announced

January 9, 1981

Also NSABP’s STAR Trial Finds Raloxifene Equivalent To Tamoxifen For Breast Cancer Risk Reduction.

April 21, 2006

FDA Committee Approves NDA for Mitxantrone

March 21, 1986